Aysel Atli, MD
Interventional Pain Medicine · Raleigh, NCNPI 1912084617
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $714 and has fallen 51.7% since, to $345 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in NC, where the typical reported total is $2,787.
Across 69 payments — averaging $31.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$383
- Teva Pharmaceuticals USA, Inc.$378
- Medtronic$322
- SPR Therapeutics, Inc$173
- Boston Scientific$143
- Lilly USA, LLC$127
- plus $637 from 14 others
What the payments were for
- Food & beverage$2,163100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 19 | $383 |
| Teva Pharmaceuticals USA, Inc. | 7 | $378 |
| Medtronic(2 entities) | 8 | $322 |
| SPR Therapeutics, Inc | 3 | $173 |
| Boston Scientific | 5 | $143 |
| Lilly USA, LLC | 3 | $127 |
| MDD US Operations, LLC | 1 | $109 |
| Collegium Pharmaceutical, Inc. | 3 | $94 |
| AbbVie(2 entities) | 5 | $88 |
| GRT US Holding, Inc. | 2 | $69 |
| Vertex | 1 | $61 |
| Scilex Pharmaceuticals Inc. | 2 | $59 |
| Nevro Corp. | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Pfizer | 1 | $19 |
| Fidia Pharma USA Inc. | 1 | $19 |
| Stimwave Technologies Incorporated | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AJOVY$333
- INTELLIS ADAPTIVESTIM$117
- Lucemyra/Lofexidine$109
- EMGALITY$100
How this compares
$2,163 in reported general payments places this provider in the 35th percentile of 45 interventional pain medicine providers in North Carolina.
See all interventional pain medicine providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 23 | $26,424 |
| Buprenorphine | 21 | $4,530 |
| Tramadol Hcl ErTramadol Hcl | 16 | $1,411 |
| Gabapentin | 139 | $1,273 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 72 | $1,162 |
| Pregabalin | 38 | $898 |
| Lidocaine Hcl ViscousLidocaine Hcl | 15 | $554 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 14 | $396 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 39 | $390 |
| Celecoxib | 14 | $387 |
| Tizanidine Hcl | 46 | $339 |
| Cyclobenzaprine Hcl | 30 | $273 |
| Baclofen | 17 | $261 |
| Duloxetine Hcl | 18 | $252 |
| Oxycodone Hcl | 12 | $228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $94 | $26,42423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 45 interventional pain medicine providers in North Carolina.
Other interventional pain medicine in Raleigh
- Allyson BryantRaleigh$2K
- Daljit ButtarRaleigh$380
- Timothy ChafinAhoskie$59K
- Robert WilsonSalisbury$37K
- John MansfieldAsheville$25K
- Erin ChaneyJacksonville$22K
- Kevin CostelloGreenville$22K
- Scott JohnstonJacksonville$20K
- Harsh GovilStatesville$19K
- Troy GingerichCharlotte$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.